RifabutinOther Names: Mycobutin, RFB Drug Class: Opportunistic Infections and Coinfections
What is rifabutin?
Rifabutin is an antibacterial prescription medicine approved by the U.S. What is an Opportunistic Infection? fact sheet.(FDA) for the prevention of Mycobacterium avium complex (MAC) disease in people with advanced HIV Infection. Disseminated MAC disease, also called disseminated MAC infection, is an of HIV. An opportunistic infection is an infection that occurs more frequently or is more severe in people with weakened immune systems—such as those infected with HIV—than in people with healthy immune systems. To learn more about opportunistic infections, read the AIDSinfo
Rifabutin can also be used off-label to prevent and treat other opportunistic infections of HIV infection.refers to use of an FDA-approved medicine in a manner different from that described on the medicine label. Good medical practice and the best interests of a patient sometimes require that a medicine be used off-label.
How is rifabutin used in people with HIV?
The Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents, prepared by the Centers for Disease Control and Prevention (CDC), the(NIH), and the HIV Medicine Association of the Diseases Society of America (IDSA-HIVMA), includes recommendations on the HIV-related uses of rifabutin to:
- Disseminated MAC disease from occurring the first time (called ) and from recurring (called secondary prophylaxis or ).
- Disseminated MAC disease. (This is an off-label use.)
- Latent (TB) infection to prevent the infection from advancing to active TB disease. (This is an off-label use.)
- Active TB disease. (This is an off-label use.)
What should I tell my health care provider before taking rifabutin?
Before taking rifabutin, tell your health care provider:
- If you are allergic to rifabutin or any other medicines.
- About any medical conditions you have or have had, for example, or problems.
- About anything that could affect your ability to take medicines, such as difficulty swallowing or remembering to take pills.
- If you are pregnant or plan to become pregnant. Whether rifabutin can harm an unborn baby is unknown. Rifabutin should be used during pregnancy only if the potential benefits outweigh the risks. Talk to your health care provider about possible risks with taking rifabutin when pregnant.
- If you are breastfeeding or plan to breastfeed. Do not breastfeed if you have HIV.
- About other prescription and nonprescription medicines, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Rifabutin may affect the way other medicines or products work, and other medicines or products may affect how rifabutin works. Ask your health care provider if there are interactions between rifabutin and the other medicines you take.
Ask your health care provider about possible side effects from rifabutin. Your health care provider will tell you what to do if you have side effects.
How should I take rifabutin?
Take rifabutin according to your health care provider’s instructions. Your health care provider will tell you how much rifabutin to take and when to take it. Before you start rifabutin and each time you get a refill, read any printed information that comes with your medicine.
How should rifabutin be stored?
- Store rifabutin capsules at room temperature, 68°F to 77°F (20°C to 25°C).
- Do not use rifabutin if the original seal over the container opening is broken or missing.
- Throw away rifabutin that is no longer needed or expired (out of date). Follow FDA guidelines on how to safely dispose of unused medicine.
- Keep rifabutin and all medicines out of reach of children.
Where can I find more information about rifabutin?
More information about rifabutin is available:
- Recommendations on the HIV-related uses of rifabutin, from the Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents, prepared by CDC, NIH, and IDSA-HIVMA.
- Rifabutin-related research studies, from the AIDSinfo database of study summaries.
The above Patient Version drug summary is based on the following FDA label(s): Capsule.
Last Reviewed: June 19, 2017